436 related articles for article (PubMed ID: 22257150)
1. A guide to rational dosing of monoclonal antibodies.
Bai S; Jorga K; Xin Y; Jin D; Zheng Y; Damico-Beyer LA; Gupta M; Tang M; Allison DE; Lu D; Zhang Y; Joshi A; Dresser MJ
Clin Pharmacokinet; 2012 Feb; 51(2):119-35. PubMed ID: 22257150
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetics of sifalimumab, an investigational anti-interferon-α monoclonal antibody, in systemic lupus erythematosus.
Narwal R; Roskos LK; Robbie GJ
Clin Pharmacokinet; 2013 Nov; 52(11):1017-27. PubMed ID: 23754736
[TBL] [Abstract][Full Text] [Related]
3. Fixed dosing versus body size-based dosing of monoclonal antibodies in adult clinical trials.
Wang DD; Zhang S; Zhao H; Men AY; Parivar K
J Clin Pharmacol; 2009 Sep; 49(9):1012-24. PubMed ID: 19620385
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetic analysis of sifalimumab from a clinical phase IIb trial in systemic lupus erythematosus patients.
Zheng B; Yu XQ; Greth W; Robbie GJ
Br J Clin Pharmacol; 2016 May; 81(5):918-28. PubMed ID: 26659791
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetic analysis of patritumab, a HER3 inhibitor, in subjects with advanced non-small cell lung cancer (NSCLC) or solid tumors.
Yoshiba S; Jansen M; Matsushima N; Chen S; Mendell J
Cancer Chemother Pharmacol; 2016 May; 77(5):987-96. PubMed ID: 27017616
[TBL] [Abstract][Full Text] [Related]
6. Model-Aided Adults-to-Children Pharmacokinetic Extrapolation and Empirical Body Size-Based Dosing Exploration for Therapeutic Monoclonal Antibodies-Is Allometry a Reasonable Choice?
Xu Y; Langevin BA; Zhou H; Xu Z
J Clin Pharmacol; 2020 Dec; 60(12):1573-1584. PubMed ID: 32578225
[TBL] [Abstract][Full Text] [Related]
7. Fixed dosing of intravenous tocilizumab in rheumatoid arthritis. Results from a population pharmacokinetic analysis.
Bastida C; Ruiz-Esquide V; Pascal M; de Vries Schultink AHM; Yagüe J; Sanmartí R; Huitema ADR; Soy D
Br J Clin Pharmacol; 2018 Apr; 84(4):716-725. PubMed ID: 29314183
[TBL] [Abstract][Full Text] [Related]
8. Rationale for fixed dosing of pertuzumab in cancer patients based on population pharmacokinetic analysis.
Ng CM; Lum BL; Gimenez V; Kelsey S; Allison D
Pharm Res; 2006 Jun; 23(6):1275-84. PubMed ID: 16715358
[TBL] [Abstract][Full Text] [Related]
9. Quantitative prediction of human pharmacokinetics for monoclonal antibodies: retrospective analysis of monkey as a single species for first-in-human prediction.
Dong JQ; Salinger DH; Endres CJ; Gibbs JP; Hsu CP; Stouch BJ; Hurh E; Gibbs MA
Clin Pharmacokinet; 2011 Feb; 50(2):131-42. PubMed ID: 21241072
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics of therapeutic monoclonal antibodies.
Dirks NL; Meibohm B
Clin Pharmacokinet; 2010 Oct; 49(10):633-59. PubMed ID: 20818831
[TBL] [Abstract][Full Text] [Related]
11. Switching from body surface area-based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis.
Gupta N; Zhao Y; Hui AM; Esseltine DL; Venkatakrishnan K
Br J Clin Pharmacol; 2015 May; 79(5):789-800. PubMed ID: 25377318
[TBL] [Abstract][Full Text] [Related]
12. Fixed Dosing of Monoclonal Antibodies in Oncology.
Hendrikx JJMA; Haanen JBAG; Voest EE; Schellens JHM; Huitema ADR; Beijnen JH
Oncologist; 2017 Oct; 22(10):1212-1221. PubMed ID: 28754722
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Weight Thresholds for Pediatric Patients to Use Adult Dosage of Therapeutic Monoclonal Antibodies.
Yang N; Xu MC; Yao Z
J Clin Pharmacol; 2019 Oct; 59(10):1309-1318. PubMed ID: 31050000
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of dosing strategy for pembrolizumab for oncology indications.
Freshwater T; Kondic A; Ahamadi M; Li CH; de Greef R; de Alwis D; Stone JA
J Immunother Cancer; 2017; 5():43. PubMed ID: 28515943
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics of busulfan in children: increased evidence for body surface area and allometric body weight dosing of busulfan in children.
Trame MN; Bergstrand M; Karlsson MO; Boos J; Hempel G
Clin Cancer Res; 2011 Nov; 17(21):6867-77. PubMed ID: 21918171
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetic analysis of danvatirsen supporting flat dosing switch.
Xu H; Tong X; Mugundu G; Scott ML; Cook C; Arfvidsson C; Pease E; Zhou D; Lyne P; Al-Huniti N
J Pharmacokinet Pharmacodyn; 2019 Feb; 46(1):65-74. PubMed ID: 30661177
[TBL] [Abstract][Full Text] [Related]
17. Refinement of the population pharmacokinetic model for the monoclonal antibody matuzumab: external model evaluation and simulations.
Kuester K; Kovar A; Lüpfert C; Brockhaus B; Kloft C
Clin Pharmacokinet; 2009; 48(7):477-87. PubMed ID: 19691369
[TBL] [Abstract][Full Text] [Related]
18. Fixed dosing versus body size-based dosing of therapeutic peptides and proteins in adults.
Zhang S; Shi R; Li C; Parivar K; Wang DD
J Clin Pharmacol; 2012 Jan; 52(1):18-28. PubMed ID: 21233304
[TBL] [Abstract][Full Text] [Related]
19. Clinical Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies Approved to Treat Rheumatoid Arthritis.
Ternant D; Bejan-Angoulvant T; Passot C; Mulleman D; Paintaud G
Clin Pharmacokinet; 2015 Nov; 54(11):1107-23. PubMed ID: 26123705
[TBL] [Abstract][Full Text] [Related]
20. Selection of dosing regimen with WST11 by Monte Carlo simulations, using PK data collected after single IV administration in healthy subjects and population PK modeling.
Fabre MA; Fuseau E; Ficheux H
J Pharm Sci; 2007 Dec; 96(12):3444-56. PubMed ID: 17854075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
